scispace - formally typeset
T

Thomas W. Wakefield

Researcher at University of Michigan

Publications -  407
Citations -  23278

Thomas W. Wakefield is an academic researcher from University of Michigan. The author has contributed to research in topics: Venous thrombosis & Thrombosis. The author has an hindex of 68, co-authored 395 publications receiving 20620 citations. Previous affiliations of Thomas W. Wakefield include Conrad Hotels & Scripps Research Institute.

Papers
More filters
Journal ArticleDOI

Internal iliac venous aneurysm associated with pelvic venous insufficiency.

TL;DR: An instance of unilateral, primary left internal iliac venous aneurysm and associated pelvic venous insufficiency is reported and following extensive workup for alternative causes, the aneurYSm and left gonadal vein were coil embolized with good effect.
Journal ArticleDOI

Temporary facial nerve palsy during carotid endarterectomy under local anesthesia.

TL;DR: A case of temporary facial nerve palsy during a carotid endarterectomy performed under regional anesthesia supplemented with local anesthetic after inadequate cervical plexus blockade is reported.
Journal ArticleDOI

Use of GMI-1271, an E-selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis.

TL;DR: GMI‐1271, a potent small‐molecule E‐selectin antagonist, has been shown in mouse models to decrease thrombus burden with a low risk of bleeding.
Journal ArticleDOI

1D-1H-nuclear magnetic resonance metabolomics reveals age-related changes in metabolites associated with experimental venous thrombosis

TL;DR: 1D-(1)H-nuclear magnetic resonance-metabolite profiling was used to identify, for the first time, in an experimental model, three potential metabolites, glutamine, phenylalanine, and proline, associated with age-related VT.
Journal ArticleDOI

An Aspirin a Day to Keep the Clots Away Can Aspirin Prevent Recurrent Thrombosis in Extended Treatment for Venous Thromboembolism

TL;DR: Patients presenting with deep vein thrombosis (DVT) in the absence of any identifiable risk factors are said to have an unprovoked or idiopathic DVT and are evaluated for long-term anticoagulation after initial treatment with 3 to 6 months of antICOagulation.